How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

861 results for

Neuraminidase Inhibitor

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. (PubMed)

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cystic fibrosis is the most common, life-threatening, recessively inherited disease of Caucasian populations. It is a multisystem disorder caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein which is important in producing sweat, digestive juices and mucus.The impaired or absent function of this protein results in the production of viscous mucus (...) the neuraminidase inhibitors zanamivir and oseltamivir. These inhibitors can limit the infection and prevent the spread of the virus.To assess the effects of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent

2016 Cochrane

2. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses

Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses SCIENTIFIC ADVICE www.ecdc.europa.eu Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza Review of recent systematic reviews and meta-analyses ECDC SCIENTIFIC ADVICE Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza – review of recent systematic reviews and meta-analyses ii (...) (University of Michigan School of Public Health); Jonathan Nguyen-Van-Tam (University of Nottingham) ECDC representatives: Mike Catchpole; Piotr Kramarz; Pasi Penttinen; Angus Nicoll; Kari Johansen; Emmanuel Robesyn; Eeva Broberg; René Snacken; Cornelia Adlhoch; Brenna Deckert; Luciana Muresan Suggested citation: European Centre for Disease Prevention and Control. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza – review of recent systematic reviews and meta

2017 European Centre for Disease Prevention and Control - Expert Opinion

3. Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016)

Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016) DRAFT SCIENTIFIC ADVICE FOR CONSULTATION ECDC PRELIMINARY SCIENTIFIC ADVICE Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza Review of recent systematic reviews and meta-analyses ii This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Pasi Penttinen and Kari Johansen. Contributing authors Emmanuel Robesyn, Eeva Broberg (...) under copyright and cannot be used for purposes other than this publication without the express permission of the copyright holder. SCIENTIFIC ADVICE Expert Opinion on Neuraminidase inhibitors for prevention and treatment of influenza iii Contents Abbreviations iv Glossary v Executive summary 1 Background 3 Request for ECDC Expert Opinion 5 Methods 6 Results and discussion 8 General characteristics of the systematic reviews and meta-analyses reviewed by ECDC expert group 8 Treatment of outpatients

2016 European Centre for Disease Prevention and Control - Expert Opinion

4. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. (PubMed)

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cystic fibrosis is the most common, life-threatening, recessively inherited disease of Caucasian populations. It is a multisystem disorder caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein which is important in producing sweat, digestive juices and mucus.The impaired or absent function of this protein results in the production of viscous mucus (...) the neuraminidase inhibitors zanamivir and oseltamivir. These inhibitors can limit the infection and prevent the spread of the virus.To assess the effects of neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent

2014 Cochrane

5. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes (PubMed)

Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes Several subtypes of avian influenza viruses (AIVs) are emerging as novel human pathogens, and the frequency of related infections has increased in recent years. Although neuraminidase (NA) inhibitors (NAIs) are the only class of antiviral drugs available for therapeutic intervention for AIV-infected patients, studies on NAI resistance among AIVs have been (...) , and I427L) or previously reported in other subtypes (E119A/D/V, Q136K, E276D, R292K, and R371K). Our results demonstrate that each NA subtype possesses unique NAI resistance markers, and knowledge of these substitutions in AIVs is important in facilitating antiviral susceptibility monitoring of NAI resistance in AIVs.IMPORTANCE The frequency of human infections with avian influenza viruses (AIVs) has increased in recent years. Despite the availability of vaccines, neuraminidase inhibitors (NAIs

Full Text available with Trip Pro

2017 Journal of virology

6. Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals (PubMed)

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals The neuraminidase (NA) inhibitors are the only class of antivirals approved for the treatment and prophylaxis of influenza that are effective against currently circulating strains. In addition to their use in treating seasonal influenza, the NA inhibitors have been stockpiled by a number of countries for use in the event of a pandemic (...) . It is therefore important to monitor the susceptibility of circulating influenza viruses to this class of antivirals. There are different types of assays that can be used to assess the susceptibility of influenza viruses to the NA inhibitors, but the enzyme inhibition assays using either a fluorescent substrate or a chemiluminescent substrate are the most widely used and recommended. This protocol describes the use of a fluorescence-based assay to assess influenza virus susceptibility to NA inhibitors

Full Text available with Trip Pro

2017 Journal of visualized experiments : JoVE

7. Use of neuraminidase inhibitors in influenza

Use of neuraminidase inhibitors in influenza Improving School Governance | 1 Use of neuraminidase inhibitors in influenza Image: Swine Flu virus Sculpture Luke Jerram/Wellcome Images October 2015 1 Use of Neuraminidase Inhibitors in Influenza Contents 1. Summary Background Commentary on the recent publications Pipeline of new drugs and resistance Research priorities Preparedness 3 2. Introduction Terms of reference and conduct of this review Current influenza guidelines 6 3. Studies considered (...) that could result from an influenza strain causing severe disease. The principal class of antivirals licensed for the treatment and prophylaxis of seasonal and pandemic influenza are neuraminidase inhibitors (NAIs), specifically oseltamivir (trade name: Tamiflu) and zanamivir (trade name: Relenza). • Questions have been raised for some years about the efficacy and effectiveness of these NAIs and whether this justifies their being part of the UK government’s response to influenza, and particularly whether

2015 Academy of Medical Sciences

8. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. (PubMed)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. Baloxavir marboxil (formerly S-033188) is a first-in-class, orally available, cap-dependent endonuclease inhibitor licensed in Japan and the USA for the treatment of influenza virus infection. We evaluated the efficacy of delayed oral treatment with baloxavir marboxil in combination with a neuraminidase inhibitor in a mouse model (...) of lethal influenza virus infection.The inhibitory potency of baloxavir acid (the active form of baloxavir marboxil) in combination with neuraminidase inhibitors was tested in vitro. The therapeutic effects of baloxavir marboxil and oseltamivir phosphate, or combinations thereof, were evaluated in mice lethally infected with influenza virus A/PR/8/34; treatments started 96 h post-infection.Combinations of baloxavir acid and neuraminidase inhibitor exhibited synergistic potency against viral replication

Full Text available with Trip Pro

2018 Journal of Antimicrobial Chemotherapy

9. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. (PubMed)

Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. Objective To evaluate the possible effects of exposure to neuraminidase inhibitors during embryo-fetal life with respect to adverse neonatal outcomes and congenital malformations.Design Population based multinational observational cohort study and meta-analysis.Setting National registers covering information on maternal healthcare, births (...) , and prescriptions in Denmark, Norway, and Sweden and the EFEMERIS database from the Haute-Garonne district in France.Participants All women together with their singleton infants born between 1 January 2008 and 31 December 2010. Only infants born at 154 days of gestation or later were included. Infants were defined as exposed if the women filled a prescription during pregnancy for either of the two neuraminidase inhibitors oseltamivir or zanamivir.Main outcomes Low birth weight, low Apgar score, preterm birth

Full Text available with Trip Pro

2017 BMJ

10. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. (PubMed)

A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Baloxavir marboxil (baloxavir) is the first cap-dependent endonuclease inhibitor being studied for the treatment of influenza in single oral dosing regimen. This network meta-analysis (NMA) evaluated the efficacy and safety of baloxavir compared to other antivirals for influenza in otherwise healthy patients.A systematic

2019 Current medical research and opinion

11. Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. (PubMed)

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada. We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.

Full Text available with Trip Pro

2019 Emerging Infectious Diseases

12. An activity-integrated strategy of the identification, screening and determination of potential neuraminidase inhibitors from Radix Scutellariae. (PubMed)

An activity-integrated strategy of the identification, screening and determination of potential neuraminidase inhibitors from Radix Scutellariae. Small molecules isolated from herbal medicines (HMs) were identified as the potential neuraminidase inhibitors which are effective in influenza prevention and treatment. Unfortunately, current available screen methods of small molecules isolated from HMs are inefficient and insensitive. Here a novel Ultra Performance Liquid Chromatography coupled (...) with diode-array detectors and auto-fraction collector / time-of-flight mass spectrometry (UPLC-DAD-FC/Q-TOF-MS) screening method with high efficiency was developed and validated to separate, collect, enrich, identify and quantify potential neuraminidase inhibitors from Radix Scutellariae. The results showed that 26 components with neuraminidase inhibitory activity were identified from Radix Scutellariae extracts. It was also found that the influence of origins on the quality of RS was more than

Full Text available with Trip Pro

2017 PLoS ONE

13. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. (PubMed)

Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Planning for outbreaks of influenza is a high priority public health issue for national governments. Neuraminidase inhibitors (NIs) are thought to help reduce the symptoms of influenza with several possible mechanisms proposed. NIs have been stockpiled with a view to their widespread use in the event of a pandemic. However, the evidence base for this class of agents remains a source of debate

Full Text available with Trip Pro

2012 Cochrane

14. Neuraminidase inhibitors for preventing and treating influenza in children. (PubMed)

Neuraminidase inhibitors for preventing and treating influenza in children. During epidemics, influenza attack rates in children may exceed 40%. Options for prevention and treatment currently include the neuraminidase inhibitors zanamivir and oseltamivir. Laninamivir octanoate, the prodrug of laninamivir, is currently being developed.To assess the efficacy, safety and tolerability of neuraminidase inhibitors in the treatment and prevention of influenza in children.For this update we searched (...) the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 1) which includes the Acute Respiratory Infections Group's Specialised Register, MEDLINE (1966 to January week 2, 2011) and EMBASE (January 2010 to January 2011).Double-blind, randomised controlled trials (RCTs) comparing neuraminidase inhibitors with placebo or other antiviral drugs in children aged up to and including 12 years. We also included safety and tolerability data from other types of studies.Four

2012 Cochrane

15. Should Neuraminidase Inhibitors Be Prescribed To Patients With Influenza?

Should Neuraminidase Inhibitors Be Prescribed To Patients With Influenza? Systematic Review Snapshot TAKE-HOME MESSAGE Patientswhoreceivedneuraminidaseinhibitorsforacutein?uenzawithin48hours of symptom onset began to have symptom resolution approximately 1 day sooner compared with those who received placebo. Should Neuraminidase Inhibitors Be Prescribed for Patients With In?uenza? EBEM Commentators Deepa M. Patel, MD Stephen R. Pitts, MD, MPH Department of Emergency Medicine Emory University (...) studies were excluded, as well as those with insuf?cient information or discrepancies in the data. DATA EXTRACTION AND SYNTHESIS Pertinent data included time to ?rst symptom alleviation and ANNALS OF EMERGENCY MEDICINE JANUARY 2014 54 Annals of Emergency Medicine Volume 63, no. 1 : January 2014and/or sore throat.” 1 Given the eco- nomic effect and increased public awareness during the 2009 H1N1 pandemic, neuraminidase inhibitors have received increased attention. Medical costs totaling $10.4 billion

2013 Annals of Emergency Medicine Systematic Review Snapshots

16. Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan. (PubMed)

Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan. Neuraminidase inhibitors (NAIs) reduce influenza symptoms but clear evidence of relationships between viral titer reduction and symptom alleviation is lacking. This open-label, randomized study evaluated differences in viral dynamics between NAIs, and relationships between viral dynamics and influenza symptoms (trial registration

2018 Expert review of anti-infective therapy

17. Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2018 Clinical Trials

18. Treatment of influenza with neuraminidase inhibitors. (PubMed)

Treatment of influenza with neuraminidase inhibitors. Seasonal and pandemic influenza are major causes of morbidity and mortality globally. Neuraminidase inhibitors (NAIs) are the only class of antiviral agent recommended for the treatment of currently circulating strains of influenza. There has previously been controversy over the level of evidence for patient benefit with NAIs. We review here the current evidence base for the clinical impact of treatment of influenza with NAIs.Meta-analysis

2018 Current Opinion in Infectious Diseases

19. Synthesis, in-Vitro and in Silico Studies of Azo-Based Calix[4]arenes as Antibacterial Agent and Neuraminidase Inhibitor: A New Look Into an Old Scaffold (PubMed)

Synthesis, in-Vitro and in Silico Studies of Azo-Based Calix[4]arenes as Antibacterial Agent and Neuraminidase Inhibitor: A New Look Into an Old Scaffold Calixarene derivatives are reported as potential therapeutic agents. Azo derivatives of calixarenes have not been given much consideration to explore their biomedical applications. In the present study, some azo-based derivatives of calix[4]arene were synthesized and characterized and their antibacterial and antiviral potentials were studied (...) viral (neuraminidase) receptor. Some of the derivatives showed good interaction with the active site of bacterial and neuraminidase enzymes through hydrogen, hydrophobic and pi-pi interactions, and could inhibit the activity of the selected enzymes.

Full Text available with Trip Pro

2018 Frontiers in chemistry

20. Neuraminidase Inhibitors in Influenza Treatment and Prevention–Is It Time to Call It a Day? (PubMed)

Neuraminidase Inhibitors in Influenza Treatment and Prevention–Is It Time to Call It a Day? Stockpiling neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir is part of a global effort to be prepared for an influenza pandemic. However, the contribution of NAIs for the treatment and prevention of influenza and its complications is largely debatable due to constraints in the ability to control for confounders and to explore unobserved areas of the drug effects. For this study, we

Full Text available with Trip Pro

2018 Viruses

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>